LOGIN  |  REGISTER
C4 Therapeutics
Terns Pharmaceuticals

KORU Medical Systems to Host Investor Day on December 5, 2023

November 28, 2023 | Last Trade: US$3.67 0.05 1.38

MAHWAH, N.J. / Nov 28, 2023 / Business Wire / KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced it will host an investor day at the Mahwah, NJ headquarters on Tuesday, December 5, 2023, from 10:00 a.m. to 12:00 p.m. Eastern Time. The event will include presentations by members of management and an expert immunologist. The presentations will cover KORU Medical’s key markets, growth strategy, product portfolio, and operational and financial performance.

In-person attendance for the event requires advanced registration. Please email Hannah Jeffrey at This email address is being protected from spambots. You need JavaScript enabled to view it. by December 1, 2023, to register.

For those who cannot attend in-person, a live and archived webcast of the presentations will be available on the News/Events page of the Investors section of KORU Medical System's website at www.korumedical.com.

About KORU Medical Systems

KORU Medical Systems develops, manufactures, and commercializes innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients around the world. The FREEDOM™ Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The FREEDOM™ Infusion System is used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page